Antidopaminergic effects of leucine and genistein on shizophrenic rat models

Neurosciences

Volumn 18, Issue 3, 2013, Pages 235-241

  Suresh, Palle ^a   Raju, Akondi B ^a  

^a ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR BLOCKING AGENT; GENISTEIN; HALOPERIDOL; LEUCINE;

AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDOPAMINERGIC ACTIVITY; ARTICLE; CATALEPSY; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; FOOTSHOCK; INDIA; LOCOMOTION; MONOTHERAPY; NONHUMAN; RAT; RAT MODEL; SCHIZOPHRENIA; STEREOTYPY;

EID: 84911393655     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Kuperberg GR. Language in schizophrenia Part 1: an introduction. Lang Linguist Compass 2010; 4: 576-589.
2. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003; 27: 269-306.
3. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-913.
4. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring newevidence. Int J Neuropsychopharmacol 2004; 7: 1-5.
5. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135: 165-173.
6. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hofman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169: 215-233.
7. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol 2001; 53: 425-432.
8. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001; 21: 1809-1818.
9. Jørgensen M, Vendelbo B, Skakkebaek NE, Lefers H. Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect 2000; 108: 403-412.
10. Leung LK, Po LS, Lau TY, Yuen YM. Effect of dietary favonols on oestrogen receptor transactivation and cell death induction. Br J Nutr 2004; 91: 831-839.
11. Huber TJ, Borsutzky M, Schneider U, Emrich HM. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr Scand 2004; 109: 269-274.
12. Kulkarni J, Riedel A, Rde AR, Castella. Estrogen-a potential treatment for schizophrenia. Schizophr Res 2001; 48: 137-144.
13. Munro IC, Harwood M, Hlywka JJ. Soy isofavones: a safety review. Nutr Rev 2003; 61: 1-33.
14. Blomstrand E. A role for branched-chain amino acids in reducing central fatigue. J Nutr 2006; 136: 544S-547S.
15. Fernstrom JD, Fernstrom MH. Tyrosine, Phenylalanine, and Catecholamine Synthesis and Function in the brain. J Nutr 2007; 137: 1539S-1547S.
16. Barros HM, Leite JR. Effects of acute and chronic carbamazepine administration on apomorphine-elicited stereotypy. Eur J Pharmacol 1986; 123: 345-349.
17. Champatisingh D, Sahu PK, Pal A, Nanda GS. Anticataleptic and antiepileptic activity of ethanolic extract of leaves of Mucuna pruriens: A study on role of dopaminergic system in epilepsy in albino rats. Indian J Pharmacol 2011; 43: 197-199.
18. Kasture SB. A Handbook of Experiments in Pre-clinical Pharmacology. 1st ed. India: Career Publications; 2006. p. 10-43.
19. Krantz JC, Jellef Carr C, Aviado DM. Pharmacologic principle of medicinal practice. Pharmacy and dentistry. 8th ed. Baltimore: Williams & Wilkins; 1972. p. 276-287.
20. Pregelj P. Neurobiological aspects of psychosis and gender. Psychiatr Danub 2009; 21 Suppl 1: 128-131.
21. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002; 27: 12-27.
22. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357-384.
23. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002; 27: 12-27.
24. Olsen L, Hansen T, Jakobsen KD, Djurovic S, Melle I, Agartz I, et al. The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples. BMC Med Genet 2008; 9: 39.
25. Boulware MI, Mermelstein PG. Te influence of estradiol on nervous system function. Drug News Perspect 2005; 18: 631-637.
26. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29-60.
27. Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 2000; 151: 99-120.
28. Weiss F, Tanzer DJ, Ettenberg A. Opposite actions of CCK-8 on amphetamine induced hyperlocomotion and stereotypy following intra cerebro ventricular and intraaccumbens injections in rats. Pharmacol Biochem Behav 1988; 30: 309-317.
29. Antoniou K, Kafetzopoulos E. Behavioral effects of amphetamine and apomorphine after striatal lesions in the rat. Pharmacol Biochem Behav 1992; 43: 705-722.
30. Ljunberg T, Ungerstedt U. Different behavioural patterns induced by apomorphine: evidence that the method of administration determines the behavioural response to the drug. Eur J Pharmacol 1977; 46: 41-50.
31. Ljunberg T, Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion. Psychopharmacol 1978; 56: 239-247.
32. Robbins TW. The acquisition of responding with conditioned reinforcement: effects of pipradrol, methylphenidate, d-amphetamine, and nomifensine. Psychopharmacol 1978; 58: 79-87.
33. Strombom U. Central receptor agonist's affects on motor activity and rate of tyrosine hydroxylation in mouse brain Naunyn-Schmied archive. Pharmacology 1976; 292: 167.
34. Costall B, Lim SK, Naylor RJ. Characterization of the mechanisms by which purported dopamine agonists reduced spontaneous activity of mice. European Journal of Pharmacology 1981; 73: 175.
35. File SE, Lucy JN, Nabbuh PS. The role of benzodiazepine receptor in mediating longlasting anticonvulsant effect and the lateappearing reduction in motor activity exploration. Psychopharmacology 1989; 97: 349-354.
36. Rang HP, Dale MM, Rilter JM. Pharmacology. 4th ed. Edinburgh: Churchill Livingstone; 1999.
37. Baldessarini RJ. Drugs and treatment of psychiatric disorders. In: Gilman AG, Goodman, LS. Goodman & Gilman's the pharmacological basis of therapeutics. 8th ed. New York, Pergamon Press; 1990. p. 383-335.
38. Bowers JR. The role of drugs in the production of schizophreniform psychoses and related disorders. In: Meltzer HY, editor. Psychopharmacology: the Third Generation of Progress. New York (NY): Raven Press; 1987. p. 819-823.
39. Losonczy MF, Davidson M, Davis KA. Te dopamine hypothesis of schizophrenia. In: Meltzer HY, editor. Psycho-pharmacology: the Tird Generation of Progress. New York (NY): Raven Press; 1987. p. 715-726.
40. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-152.
41. Fields JZ, Drucker GE, Wichlinski L, Gordon JH. Neurochemical basis for the absence of overt 'stereotyped' behaviors in rats with up-regulated striatal D2 dopamine receptors. Clin Neuropharmacol 1991; 14: 199-108.
42. Kalivas PW, Stewart J. Dopamine transmission in the initiation and and expression of drug- and stress-induced sensitization of motor activity. Brain Res 1991; 16: 223-244.
43. Seeman P. Dopamine D1 and D2 receptor selectivities of agonists and antagonists. Adv Exp Med Biol 1988; 235: 55-63.
44. Bernard B, Finkelstein ER, Everett GM. Alterations in mouse aggressive behavior and brain monoamine dynamics as a function of age. Physiol Behav 1975; 15: 731-36.
45. Tizabi Y, Toa NB, Maengwyn-Davies GD, Kopin IJ, Jacobowitz DM. Behavioral correlation of catecholamine concentration and turnover in discrete brain areas of three strains of mice. Brain Res 1979; 166: 199-105.
46. Clement J, Simler S, Ciesielski L, Mandel P, Cabib S, Puglisi-Allegra S. Agedependent changes of brain GABA levels turnover rates and shock- induced aggressive behavior in inbred strains of mice. Pharmacol Biochem Behav 1987; 26: 83-88.